Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 50 of 222

    1.

    Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer.

    Cosler LE, Lyman GH.

    Cancer Invest. 2009 Dec;27(10):953-9. No abstract available. PMID: 19909009 [PubMed - in process]Related articles

    2.

    Isolated tumor cells in breast cancer.

    Lyman GH, Peppercorn J.

    N Engl J Med. 2009 Nov 12;361(20):1994; author reply 1995-6. No abstract available. PMID: 19907048 [PubMed - in process]Related articles

    3.

    Gene expression profile assays as predictors of distant recurrence-free survival in early-stage breast cancer.

    Kuderer NM, Lyman GH.

    Cancer Invest. 2009 Nov;27(9):885-90. Review. No abstract available. PMID: 19832034 [PubMed - indexed for MEDLINE]Related articles

    4.

    Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer.

    Lyman GH.

    Cancer. 2009 Oct 13. [Epub ahead of print]PMID: 19827150 [PubMed - as supplied by publisher]Related articles

    5.

    Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer.

    Herold CI, Djulbegovic B, Hozo I, Lyman GH.

    Breast Cancer Res Treat. 2009 Oct 6. [Epub ahead of print]PMID: 19806449 [PubMed - as supplied by publisher]Related articles

    6.

    Cancer, clots and consensus: new understanding of an old problem.

    Lyman GH, Khorana AA.

    J Clin Oncol. 2009 Oct 10;27(29):4821-6. Epub 2009 Sep 14. Review. No abstract available. PMID: 19752337 [PubMed - indexed for MEDLINE]Related articles

    7.

    Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy.

    Aapro M, Schwenkglenks M, Lyman GH, Lopez Pousa A, Lawrinson S, Skacel T, Bacon P, von Minckwitz G.

    Crit Rev Oncol Hematol. 2009 Sep 10. [Epub ahead of print]PMID: 19748281 [PubMed - as supplied by publisher]Related articles

    8.

    Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action.

    Khorana AA, Streiff MB, Farge D, Mandala M, Debourdeau P, Cajfinger F, Marty M, Falanga A, Lyman GH.

    J Clin Oncol. 2009 Oct 10;27(29):4919-26. Epub 2009 Aug 31. Review.PMID: 19720907 [PubMed - indexed for MEDLINE]Related articles

    9.

    The road to romiplostim approval and beyond.

    Lyman GH.

    Oncology (Williston Park). 2009 Jul;23(8):709-10, 715. No abstract available. PMID: 19711586 [PubMed - indexed for MEDLINE]Related articles

    10.

    Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.

    Shayne M, Culakova E, Wolff D, Poniewierski MS, Dale DC, Crawford J, Lyman GH.

    Cancer. 2009 Nov 15;115(22):5319-28.PMID: 19672945 [PubMed - in process]Related articles

    11.

    Comparative effectiveness research in oncology: the need for clarity, transparency and vision.

    Lyman GH.

    Cancer Invest. 2009 Jul;27(6):593-7. No abstract available. PMID: 19557579 [PubMed - indexed for MEDLINE]Related articles

    12.

    Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.

    Lyman GH, Lalla A, Barron RL, Dubois RW.

    Clin Ther. 2009 May;31(5):1092-104.PMID: 19539110 [PubMed - indexed for MEDLINE]Related articles

    13.

    Cancer and thrombosis: back to the future renewed interest in an old problem.

    Lyman GH, Khorana AA, Kuderer NM, Lee AY.

    Cancer Invest. 2009 Jun;27(5):472-3.PMID: 19479483 [PubMed - indexed for MEDLINE]Related articles

    14.

    Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors.

    Madeb R, Golijanin D, Noyes K, Fisher S, Stephenson JJ, Long SR, Knopf J, Lyman GH, Messing EM.

    Cancer. 2009 Jun 15;115(12):2660-70.PMID: 19455607 [PubMed - indexed for MEDLINE]Related articles

    15.

    Does treatment intensity matter in superficial bladder cancer? Consensus, clinical practice, and confounding.

    Lyman GH, Kuderer NM, Freedland SJ.

    J Natl Cancer Inst. 2009 Apr 15;101(8):543-5. Epub 2009 Apr 7. No abstract available. PMID: 19351926 [PubMed - indexed for MEDLINE]Related articles

    16.

    Impact of chemotherapy dose intensity on cancer patient outcomes.

    Lyman GH.

    J Natl Compr Canc Netw. 2009 Jan;7(1):99-108. Review.PMID: 19176210 [PubMed - indexed for MEDLINE]Related articles

    17.

    Myeloid growth factors.

    Crawford J, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Goemann M, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, Michaud LB, Miyata SC, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK; National Comprehensive Cancer Network.

    J Natl Compr Canc Netw. 2009 Jan;7(1):64-83. No abstract available. PMID: 19176207 [PubMed - indexed for MEDLINE]Related articles

    18.

    Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.

    von Minckwitz G, Schwenkglenks M, Skacel T, Lyman GH, Pousa AL, Bacon P, Easton V, Aapro MS.

    Eur J Cancer. 2009 Mar;45(4):608-17. Epub 2008 Dec 26. Review.PMID: 19110415 [PubMed - indexed for MEDLINE]Related articles

    19.

    Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer.

    Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH.

    Arch Intern Med. 2008 Nov 24;168(21):2377-81.PMID: 19029504 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Variation in the cost of medications for the treatment of colorectal cancer.

    Ferro SA, Myer BS, Wolff DA, Poniewierski MS, Culakova E, Cosler LE, Scarpace SL, Khorana AA, Lyman GH.

    Am J Manag Care. 2008 Nov;14(11):717-25.PMID: 18999906 [PubMed - indexed for MEDLINE]Related articlesFree article

    21.

    Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group.

    Horan JT, Alonzo TA, Lyman GH, Gerbing RB, Lange BJ, Ravindranath Y, Becton D, Smith FO, Woods WG; Children's Oncology Group.

    J Clin Oncol. 2008 Dec 10;26(35):5797-801. Epub 2008 Oct 27.PMID: 18955460 [PubMed - indexed for MEDLINE]Related articles

    22.

    The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.

    Greenberg PL, Cosler LE, Ferro SA, Lyman GH.

    J Natl Compr Canc Netw. 2008 Oct;6(9):942-53.PMID: 18926103 [PubMed - indexed for MEDLINE]Related articles

    23.

    American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges.

    Somerfield MR, Einhaus K, Hagerty KL, Brouwers MC, Seidenfeld J, Lyman GH; American Society of Clinical Oncology.

    J Clin Oncol. 2008 Aug 20;26(24):4022-6.PMID: 18711193 [PubMed - indexed for MEDLINE]Related articles

    24.

    Cost-Effectiveness of Primary versus Secondary Prophylaxis with Pegfilgrastim in Women with Early-Stage Breast Cancer Receiving Chemotherapy.

    Ramsey SD, Liu Z, Boer R, Sullivan SD, Malin J, Doan QV, Dubois RW, Lyman GH.

    Value Health. 2008 Jul 31. [Epub ahead of print]PMID: 18673353 [PubMed - as supplied by publisher]Related articles

    25.

    Moving beyond febrile neutropenia.

    Lyman GH, Kuderer NM.

    Support Cancer Ther. 2005 Jan 1;2(2):95-7. No abstract available. PMID: 18628194 [PubMed - in process]Related articlesFree article

    26.

    A primer in prognostic and predictive models: development and validation of neutropenia risk models.

    Lyman GH, Kuderer NM.

    Support Cancer Ther. 2005 Apr 1;2(3):168-75.PMID: 18628168 [PubMed - in process]Related articlesFree article

    27.

    Benefits of GM-CSF Versus Placebo or G-CSF in Reducing Chemotherapy-Induced Complications: A Systematic Review of the Literature.

    Dubois RW, Pinto LA, Bernal M, Badamgarav E, Lyman GH.

    Support Cancer Ther. 2004 Oct 1;2(1):34-41.PMID: 18628156 [PubMed - in process]Related articlesFree article

    28.

    Prophylactic pegfilgrastim significantly reduces febrile neutropenia during moderately myelosuppressive chemotherapy.

    Price N, Jain VK, Lyman GH.

    Support Cancer Ther. 2004 Jul 1;1(4):207-9. No abstract available. PMID: 18628143 [PubMed - in process]Related articlesFree article

    29.

    Epidemiology of febrile neutropenia.

    Lyman GH, Kuderer NM.

    Support Cancer Ther. 2003 Oct 1;1(1):23-35.PMID: 18628128 [PubMed - in process]Related articlesFree article

    30.

    Optimal cancer care across the spectrum of life and disease.

    Lyman GH, Hauser RS.

    Am J Manag Care. 2008 May;14(5):262-4. No abstract available. PMID: 18471030 [PubMed - indexed for MEDLINE]Related articlesFree article

    31.

    Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.

    Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, Lyman GH, Nevins JR, Potti A.

    JAMA. 2008 Apr 2;299(13):1574-87.PMID: 18387932 [PubMed - indexed for MEDLINE]Related articlesFree article

    32.

    Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy.

    Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH.

    Value Health. 2008 Mar-Apr;11(2):172-9.PMID: 18380630 [PubMed - indexed for MEDLINE]Related articles

    33.

    Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.

    Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D, Lyman GH.

    J Natl Compr Canc Netw. 2008 Feb;6(2):109-18.PMID: 18319047 [PubMed - indexed for MEDLINE]Related articles

    34.

    Recommendations on the use of 18F-FDG PET in oncology.

    Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF.

    J Nucl Med. 2008 Mar;49(3):480-508. Epub 2008 Feb 20.PMID: 18287273 [PubMed - indexed for MEDLINE]Related articlesFree article

    35.

    Development and validation of a predictive model for chemotherapy-associated thrombosis.

    Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW.

    Blood. 2008 May 15;111(10):4902-7. Epub 2008 Jan 23.PMID: 18216292 [PubMed - indexed for MEDLINE]Related articlesFree article

    36.

    Estimating net benefits and harms of screening mammography in women age 40 to 49 years.

    Djulbegovic B, Hozo I, Lyman GH.

    Ann Intern Med. 2007 Dec 18;147(12):882. No abstract available. PMID: 18087062 [PubMed - indexed for MEDLINE]Related articlesFree article

    37.

    Agents under investigation for the treatment and prevention of neutropenia.

    Huston A, Lyman GH.

    Expert Opin Investig Drugs. 2007 Nov;16(11):1831-40. Review.PMID: 17970641 [PubMed - indexed for MEDLINE]Related articles

    38.

    American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.

    Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW; American Society of Clinical Oncology.

    J Clin Oncol. 2007 Dec 1;25(34):5490-505. Epub 2007 Oct 29. Review.PMID: 17968019 [PubMed - indexed for MEDLINE]Related articles

    39.

    Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients.

    Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH.

    Cancer. 2007 Nov 15;110(10):2339-46.PMID: 17918266 [PubMed - indexed for MEDLINE]Related articlesFree article

    40.

    Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.

    Shayne M, Culakova E, Poniewierski MS, Wolff D, Dale DC, Crawford J, Lyman GH.

    Cancer. 2007 Oct 1;110(7):1611-20.PMID: 17705197 [PubMed - indexed for MEDLINE]Related articlesFree article

    41.

    A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications.

    Kuderer NM, Khorana AA, Lyman GH, Francis CW.

    Cancer. 2007 Sep 1;110(5):1149-61. Review.PMID: 17634948 [PubMed - indexed for MEDLINE]Related articlesFree article

    42.

    Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

    Kuderer NM, Dale DC, Crawford J, Lyman GH.

    J Clin Oncol. 2007 Jul 20;25(21):3158-67. Review.PMID: 17634496 [PubMed - indexed for MEDLINE]Related articles

    43.

    Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens.

    Griggs JJ, Culakova E, Sorbero ME, Poniewierski MS, Wolff DA, Crawford J, Dale DC, Lyman GH.

    J Clin Oncol. 2007 Jun 20;25(18):2522-7.PMID: 17577029 [PubMed - indexed for MEDLINE]Related articles

    44.

    Granulocyte colony-stimulating factors: finding the right indication.

    Lyman GH, Shayne M.

    Curr Opin Oncol. 2007 Jul;19(4):299-307. Review.PMID: 17545791 [PubMed - indexed for MEDLINE]Related articles

    45.

    Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.

    Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D, Crawford J, Lyman GH.

    Pharmacoeconomics. 2007;25(4):343-51.PMID: 17402806 [PubMed - indexed for MEDLINE]Related articles

    46.

    The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients.

    Blumberg N, Zhao H, Wang H, Messing S, Heal JM, Lyman GH.

    Transfusion. 2007 Apr;47(4):573-81.PMID: 17381614 [PubMed - indexed for MEDLINE]Related articles

    47.

    Risks and consequences of chemotherapy-induced neutropenia.

    Lyman GH.

    Clin Cornerstone. 2006;8 Suppl 5:S12-8. Review.PMID: 17379159 [PubMed - indexed for MEDLINE]Related articles

    48.

    Chemotherapy dose intensity and quality cancer care.

    Lyman GH.

    Oncology (Williston Park). 2006 Dec;20(14 Suppl 9):16-25. Review.PMID: 17370925 [PubMed - indexed for MEDLINE]Related articles

    49.

    Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.

    Lyman GH, Kleiner JM.

    J Natl Compr Canc Netw. 2007 Feb;5(2):217-28.PMID: 17335690 [PubMed - indexed for MEDLINE]Related articles

    50.

    Myeloid growth factors. Clinical practice guidelines in oncology.

    Crawford J, Althaus B, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Heaney ML, Htoy S, Kloth DD, Lyman GH, Messersmith WA, Michaud LB, Miyata SC, Robbins A, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK; National Comprehensive Cancer Network (NCCN).

    J Natl Compr Canc Netw. 2007 Feb;5(2):188-202. No abstract available. PMID: 17335688 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data

    Search details

    » See more...